118 related articles for article (PubMed ID: 9609545)
1. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Prostate; 1998 Jun; 35(4):237-42. PubMed ID: 9609545
[TBL] [Abstract][Full Text] [Related]
2. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Zaccheo T; Giudici D; di Salle E
Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
[TBL] [Abstract][Full Text] [Related]
3. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat.
di Salle E; Giudici D; Briatico G; Ornati G; Panzeri A
J Steroid Biochem Mol Biol; 1993 Nov; 46(5):549-55. PubMed ID: 8240976
[TBL] [Abstract][Full Text] [Related]
4. Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073).
Di Salle E; Briatico G; Giudici D; Ornati G; Panzeri A
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):241-8. PubMed ID: 8142301
[TBL] [Abstract][Full Text] [Related]
5. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
Zaccheo T; Giudici D; di Salle E
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):193-8. PubMed ID: 9605414
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
7. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Cancer Chemother Pharmacol; 2000; 45(1):31-7. PubMed ID: 10647498
[TBL] [Abstract][Full Text] [Related]
9. Determination of turosteride, a new inhibitor of 5 alpha-reductase, in human plasma by high-performance liquid chromatography with ultraviolet detection.
Basileo G; Casati M; Pianezzola E; Strolin Benedetti M
J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(1):117-25. PubMed ID: 9029321
[TBL] [Abstract][Full Text] [Related]
10. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
Sylvester PW; Ip MM
Prostate; 1987; 10(1):57-67. PubMed ID: 3822918
[TBL] [Abstract][Full Text] [Related]
11. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
12. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
14. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response.
Lamb JC; English H; Levandoski PL; Rhodes GR; Johnson RK; Isaacs JT
Endocrinology; 1992 Feb; 130(2):685-94. PubMed ID: 1733716
[TBL] [Abstract][Full Text] [Related]
15. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
di Salle E; Giudici D; Radice A; Zaccheo T; Ornati G; Nesi M; Panzeri A; Délos S; Martin PM
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):179-86. PubMed ID: 9605412
[TBL] [Abstract][Full Text] [Related]
16. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
Ichikawa T; Akimoto S; Shimazaki J
Endocr J; 1993 Aug; 40(4):425-30. PubMed ID: 7522799
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor.
Prahalada SR; Keenan KP; Hertzog PR; Gordon LR; Peter CP; Soper KA; van Zwieten MJ; Bokelman DL
Urology; 1994 May; 43(5):680-5. PubMed ID: 7513109
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
19. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
20. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.
Prahalada S; Rhodes L; Grossman SJ; Heggan D; Keenan KP; Cukierski MA; Hoe CM; Berman C; van Zwieten MJ
Prostate; 1998 May; 35(3):157-64. PubMed ID: 9582084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
